Drug

Becotatug clinical trials

Also written JMT101.

studies test it: 12
open now: 7
in phase 3: 4
first study started: 2017

Keep track of what changes. Save the becotatug studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

JMT101 Injection: 3
Recombinant Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Injection: 2

Development codes

JMT101: 9

Studies by the year they started

12 studies that test it; most in 2024 (4)

Studies that test becotatug, by start year
Year	Studies
2017	1
2020	1
2021	3
2024	4
2025	3

By phase

A phase 1/2 study counts in both.

Phase 1: 3
Phase 2: 6
Phase 3: 4

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Non-Small-Cell Lung: 6
Colorectal Neoplasms: 2
Squamous Cell Carcinoma of Head and Neck: 1
Nasopharyngeal Neoplasms: 1
Esophageal Squamous Cell Carcinoma: 1
Neoplasms: 1

Who runs them

Industry 11 · Other 1

Shanghai JMT-Bio Inc. (10) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · Peking University (1)

Often tested with

Tested in the same studies.

Osimertinib (4) · Irinotecan (2) · Sutantatug Envedotin (1) · Liposomal Mitoxantrone Hydrochloride (1) · Mitoxantrone (1) · Docetaxel (1) · Enlonstobart (1) · Afatinib (1)

Studies

Open first, then newest update. How each study uses becotatug is read from its arms, and is right about nine times in ten.

Testing it · 12

Codes

What other systems call becotatug · ClinicalTrials.gg INT015819

UNII (FDA) 981YA69AO3BECOTATUGOne source FDA
NCI Thesaurus C178313BecotatugOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	981YA69AO3	BECOTATUG	One source FDA
NCI Thesaurus	C178313	Becotatug	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.